When are angiotensin-converting enzyme inhibitors (ACE inhibitors) and spironolactone contraindicated?

When ACE Inhibitors and Spironolactone Are Contraindicated

ACE inhibitors are absolutely contraindicated in pregnancy due to severe fetal toxicity, and spironolactone is contraindicated in hyperkalemia, Addison's disease, and concurrent eplerenone use. 1, 2, 3, 4

ACE Inhibitor Contraindications

Absolute Contraindications

Pregnancy is the most critical contraindication for ACE inhibitors:

• Contraindicated throughout pregnancy, particularly second and third trimesters 1, 2, 3
• Causes severe fetal toxicity including:
  • Renal or tubular dysplasia
  • Oligohydramnios
  • Growth retardation
  • Ossification disorders of the skull
  • Lung hypoplasia
  • Intrauterine fetal death 1
• Must be discontinued before conception or immediately upon pregnancy detection 3
• First-trimester exposure appears less harmful but should still be avoided 3

Relative Contraindications/High-Risk Situations

Severe renal dysfunction:

• Routine use not recommended when creatinine >250 μmol/L (2.8 mg/dL) or >50% increase from baseline 5
• Requires dose reduction or discontinuation when creatinine rises to >220 μmol/L (2.5 mg/dL) 6

Hyperkalemia risk scenarios:

• Pre-existing hyperkalemia
• Concurrent use with other potassium-raising drugs 4, 7

Spironolactone Contraindications

Absolute Contraindications (FDA Label)

Per the FDA drug label, spironolactone is absolutely contraindicated in: 4

• Hyperkalemia (existing elevated potassium)
• Addison's disease (adrenal insufficiency)
• Concomitant use of eplerenone

Critical Monitoring Thresholds

Stop spironolactone immediately when: 6

• Potassium rises to ≥6.0 mmol/L
• Creatinine rises to >310 μmol/L (3.5 mg/dL)

Reduce dose by half when: 6

• Potassium rises to >5.5 mmol/L
• Creatinine rises to >220 μmol/L (2.5 mg/dL)

Combined ACE Inhibitor + Spironolactone Use

When This Combination Is Appropriate

The combination is indicated and beneficial in: 6

• Heart failure with LVEF ≤35%
• NYHA class III-IV symptoms
• Already on optimal doses of beta-blocker and ACE inhibitor (but NOT ACE inhibitor + ARB together)

High-Risk Populations Requiring Extreme Caution

The combination carries substantially increased hyperkalemia risk in: 8, 9

• Elderly patients (>70 years) - 12-fold increased risk 9
• Renal insufficiency - any baseline kidney dysfunction 8
• Diabetes mellitus 8
• Dehydration risk 8
• Concurrent medications: NSAIDs, potassium supplements, trimethoprim, heparin 4

Critical Safety Protocol

When using ACE inhibitor + spironolactone together: 6

1. Discontinue potassium supplements in heart failure patients 4
2. Maximum spironolactone dose: 25 mg daily - do not exceed 8
3. Monitoring schedule:
   • Check potassium and creatinine at 1 and 4 weeks after starting
   • Recheck at 1,2,3, and 6 months after achieving maintenance dose
   • Then every 6 months thereafter 6

Common Pitfall

Real-world hyperkalemia risk is 11-13 times higher than in clinical trials 9. The landmark RALES trial excluded patients with creatinine >2.5 mg/dL and potassium >5.0 mmol/L, but real-world patients are often more complex. The risk is particularly elevated in the first weeks of combined therapy and in older patients 9.

Pregnancy considerations: Spironolactone causes dose-dependent feminization in animal studies and should be avoided in pregnancy, though data are limited compared to ACE inhibitors 10.